APA (7th ed.) Citation

Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., . . . Langley, R. G. (2020). Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA dermatology, 156(6), 649. https://doi.org/10.1001/jamadermatol.2020.0723

Chicago Style (17th ed.) Citation

Blauvelt, Andrew, et al. "Efficacy and Safety of Continuous Risankizumab Therapy Vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial." JAMA Dermatology 156, no. 6 (2020): 649. https://doi.org/10.1001/jamadermatol.2020.0723.

MLA (9th ed.) Citation

Blauvelt, Andrew, et al. "Efficacy and Safety of Continuous Risankizumab Therapy Vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial." JAMA Dermatology, vol. 156, no. 6, 2020, p. 649, https://doi.org/10.1001/jamadermatol.2020.0723.